Fig. 1 · Structure

Documents & Downloads

AR-A 014418

Cat. No. A13728 CAS 487021-52-3

GSK-3 inhibitor

AR-A 014418 is a selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104 nM). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 μM) and over 26 other kinases. Inhibits β-amyloid-mediated neurodegeneration in hippocampal slices.

In Stock

Publications for AR-A 014418

1 publication citing this product

  1. Chia-Hui Huang, .et al. , Toxicol Appl Pharmacol, 2020, Apr 17;397:115013 PMID: 32305283

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AR-A014418 inhibits GSK3 with a reported biochemical IC50 of 104 ± 27 nM (mean ± S.E.; three independent experiments in duplicate) and ATP-competitive kinetics (Ki 38 nM). CDK2 and CDK5 IC50 values exceeded 100 µM under the tested conditions. These results describe the tested assays and do not establish GSK3β isoform selectivity. [1]

Target attribution requires model-specific controls: a later recombinant-protein study found that AR-A014418 also inhibited CDK12/cyclin K and CDK13/cyclin K in CTD-phosphorylation assays using 20–80 µM compound. These treatment concentrations are not IC50 values. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
GSK-3β (Cell-free assay) Ki 38 nM
GSK-3β (Cell-free assay) Ki 38 nM

Cellular Effect

Cell Line Activity Value Description Reference
BXPC-3 IC50 14 μM Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay [PMID: 19338355]
HuP-T3 IC50 22 μM Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay [PMID: 19338355]
MIA PaCa-2 IC50 29 μM Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay [PMID: 19338355]
Sf21 IC50 0.104 μM Inhibition of recombinant full length human GSK3beta expressed in Sf21 insect cells using biotinylated-AAEELDSRAGS(PO3H2)PQL peptide as substrate preincubated enzyme-substrate mixture for 15 to 20 mins followed by [gamma-33P]ATP addition and measured afte [PMID: 32435391]

In Vitro Studies

In 3T3 fibroblasts expressing human four-repeat tau, 4-h treatment with AR-A014418 reduced tau Ser396 phosphorylation in a concentration-dependent manner, with total-tau and vehicle controls. This cellular substrate response does not establish efficacy in animals. [1]

GSK3 inhibition, ATP competition and tested kinase selectivity

Biochemical assay · Recombinant human GSK3 enzyme assays; CDK2/cyclin E, CDK5 and a 26-kinase comparator panel [1]

AR-A014418 inhibited GSK3 and showed ATP-competitive kinetics. Selectivity applies to the tested enzymes and assay conditions; this is not proof of GSK3β isoform selectivity or exclusion of other targets.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of recombinant human GSK3 activityIC50 104 ± 27 nM (mean ± S.E.; three independent experiments, each in duplicate)[1]
ATP-competitive inhibition of GSK3Ki 38 nM[1]
Inhibition of CDK2 and CDK5IC50 >100 µM for each enzyme[1]

Literature-Reported Treatment Conditions

Exposure duration
SPA reaction: 20 min at room temperature; kinetic assay: 15 min at room temperature
Method
Radiometric scintillation proximity assay using eIF2B-derived peptide; separate glycogen-synthase-peptide kinetic assay; no-substrate blanks and activity without compound as controls
Vehicle
DMSO for kinase panel; no-compound controls for concentration-response assays
Reported limits
Final DMSO fraction in enzyme concentration-response assays not established in selected text. IC50 is an endpoint, not a treatment concentration.
Methods and source locations

Compound reported in the paper: AR-A014418

Compound-level research evidence; tested materials do not establish performance or identity of an Adooq lot.

Fig. 1A–E and caption, pp. 45940–45941; Kinase Assays and Kinetic Studies, p. 45939; IC50 Determination, p. 45940

Inhibition of recombinant human GSK3 activity: eIF2B-peptide SPA at 1 µM ATP; kinase activity normalized to activity without inhibitor — Fig. 1B caption, p. 45941; GSK3 SPA, p. 45939

ATP-competitive inhibition of GSK3: Nonlinear regression of ATP/inhibitor matrix; separate GS-peptide kinetic assay — Fig. 1D–E caption, p. 45941; Kinetic Studies, p. 45939

Inhibition of CDK2 and CDK5: Separate radiometric kinase concentration-response assays; not extrapolated to CDK12/CDK13 — Fig. 1B and caption, p. 45941

Reduced tau Ser396 phosphorylation in 3T3 fibroblasts

Cell-based study · 3T3 fibroblasts stably expressing human four-repeat tau [1]

Increasing AR-A014418 concentrations reduced tau Ser396 phosphorylation relative to total tau after 4 h. The original article gives inconsistent cellular IC50 values, so no single cellular potency is adopted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tau phosphorylation at Ser396 relative to total tauConcentration-dependent response Reduced with increasing AR-A014418 concentration[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM to 50 µM
Exposure duration
4 h
Method
Phospho-Ser396 immunoblot and total-tau Tau5 reprobe with densitometry; lithium reference and vehicle controls
Vehicle
0.1% DMSO
Reported limits
Replicate count and error estimate for the AR-A014418 tau concentration-response are not established in the selected text.
Methods and source locations

Compound reported in the paper: AR-A014418

Compound-level research evidence; tested materials do not establish performance or identity of an Adooq lot.

Fig. 5A–C and caption, p. 45943; Biological Effects, pp. 45942–45943; Analysis of Tau Phosphorylation, p. 45940

Tau phosphorylation at Ser396 relative to total tau: Western blot and densitometry; vehicle and total-tau controls; no numerical IC50 selected — Fig. 5B image/caption and associated Results, p. 45943

Additional inhibition of recombinant CDK12/cyclin K and CDK13/cyclin K

Biochemical assay · Recombinant His-CDK12/cyclin K and His-CDK13/cyclin K; GST-tagged RPB1 CTD substrate [2]

AR-A014418 reduced CTD phosphorylation by recombinant CDK12 and CDK13, limiting use of an unrestricted GSK3-selective label. No IC50 or potency ranking against GSK3 is inferred.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CDK12- and CDK13-mediated RPB1 CTD phosphorylationQualitative kinase inhibition Reduced phosphorylation with AR-A014418 in the tested concentration range[2]

Literature-Reported Treatment Conditions

Treatment concentration
20, 40 and 80 µM (Fig. 4H)
Exposure duration
1 h at 30 °C
Method
In-vitro kinase assay followed by phospho-CTD immunoblot (Ser2, Ser5, Ser7); ATP omission, DMSO and THZ531 comparator lanes
Vehicle
DMSO
Reported limits
Replicate count and numerical inhibition estimates for Fig. 4H not specified in the read caption/method; no IC50 reported there.
Methods and source locations

Compound reported in the paper: AR-A014418

Compound-level research evidence; tested materials do not establish performance or identity of an Adooq lot.

Fig. 4H and caption; Results: AR-A014418 directly targets CDK12 and CDK13 to regulate PD-L1 expression; supplementary material 002, reagent table and In vitro kinase assays, p. 11

CDK12- and CDK13-mediated RPB1 CTD phosphorylation: Immunoblot of phospho-Ser2/Ser5/Ser7; 2 mM ATP in supplement method, ATP-minus and DMSO control lanes. Concentrations are assay treatments, not IC50 values. — Fig. 4H and caption; supplement 002, In vitro kinase assays, p. 11

In Vivo Studies

In female Swiss Webster mice with insulin-deficient diabetes, AR-A014418 at 30 µmol/kg intraperitoneally each day, starting at diabetes onset for 10 weeks, improved Barnes-maze learning and novel-object recognition. Treatment did not significantly prevent the measured increases in brain tau Thr231 phosphorylation or soluble 24-kDa Aβ, and did not reduce the elevated glycemic indices. These are preventive findings in a specific mouse model. [3]

Cognitive and biochemical outcomes during chronic treatment of diabetic mice

Animal study · Adult female Swiss Webster mice with STZ-induced insulin-deficient diabetes; non-diabetic vehicle and diabetic vehicle controls [3]

Treatment started at diabetes onset and continued for 10 weeks. AR-A014418 improved Barnes-maze and object-recognition outcomes, but did not significantly prevent increases in tau Thr231 phosphorylation or soluble 24-kDa Aβ. Glycemic indices remained elevated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time to find Barnes-maze escape box and AUCBehavioral comparison Learning curve: p<0.001 versus STZ + vehicle (repeated-measures ANOVA); AUC: p<0.05 versus STZ + vehicle[3]
Novel-object explorationBehavioral comparison Memory deficit significantly prevented (p<0.05)[3]
Tau Thr231 phosphorylation/total tau and soluble 24-kDa Aβ/actinTreatment comparison Neither diabetes-associated increase was significantly prevented by AR-A014418[3]
Final blood glucose and HbA1cTreatment comparison No significant effect on diabetes-associated elevations[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
10 weeks, beginning at diabetes onset
Vehicle
4% DMSO in PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Diabetic mice + AR-A014418
30 µmol/kg
STZ-diabetic mice receiving vehicle; non-diabetic mice receiving vehicleImproved learning and recognition outcomes; no significant prevention of tau Thr231 or 24-kDa Aβ increases; glycemic indices remained elevated.[3]
Diabetic mice + AR-A014418
Model: STZ-diabetic adult female Swiss Webster mice
Reported limits: Dose remains in reported molar units. Occasional insulin rescue occurred in all diabetic groups; no Adooq lot attribution.
Methods and source locations

Compound reported in the paper: AR-A014418

Compound-level research evidence; tested materials do not establish performance or identity of an Adooq lot.

Materials and Methods: Animals, Drugs, behavioral tests, Western Blotting and statistics; Results: Barnes maze, Object recognition, Tau phosphorylation, Amyloid β; Figs. 2, 3, 5 and Table 1

Time to find Barnes-maze escape box and AUC: Five testing days after 9 weeks of treatment; Fig. 2A medians due to 300-s cutoff. No exact curve-derived values used. Exploration rate and Rota-Rod did not differ significantly between diabetic treatment and vehicle groups. — Results: Barnes maze test; Fig. 2A–D and caption

Novel-object exploration: Object recognition at week 10; one-way ANOVA with Tukey post-hoc test. No exact bar-derived percentages used. — Results: Object recognition test; Fig. 3 and caption

Tau Thr231 phosphorylation/total tau and soluble 24-kDa Aβ/actin: Brain homogenate Western blots; mean + SEM, n=6–8/group; one-way ANOVA and Tukey post-hoc test. No exact bar heights inferred. — Results: Tau phosphorylation and Amyloid β levels; Fig. 5A–B and caption

Final blood glucose and HbA1c: Table 1 and Results; no glucose-lowering mechanism inferred — Results: Diabetes; Table 1

Diabetic mice + AR-A014418 · Methods: Drugs and Animals; Results: Diabetes, Barnes maze, Object recognition, Tau phosphorylation and Amyloid β; Figs. 2, 3, 5; Table 1

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 487021-52-3
Applications GSK-3 inhibitor
Formula C12H12N4O4S
Molecular Weight 308.31
SMILES
COC1=CC=C(C=C1)CNC(=O)NC2=NC=C(S2)[N+](=O)[O-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (178.39 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Bhat R, Xue Y, Berg S, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. The Journal of biological chemistry (2003). PMID: 12928438 DOI: 10.1074/jbc.m306268200 Source material
  2. [2] Zhang G, Lan B, Zhang X, et al. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. Journal for immunotherapy of cancer (2023). PMID: 37164450 DOI: 10.1136/jitc-2022-006483 Source material
  3. [3] King MR, Anderson NJ, Guernsey LS, et al. Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. Journal of neuroscience research (2013). PMID: 23362012 DOI: 10.1002/jnr.23192 Source material

Publications

1 publication citing this product

  1. Chia-Hui Huang, .et al. , Toxicol Appl Pharmacol, 2020, Apr 17;397:115013 PMID: 32305283

Added to your cart

View Cart Checkout
Loading...